The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00168467|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 29, 2009
One important clinical challenge in older individuals is maintaining mobility in the absence of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility.
Conventional therapies have only modest effect in improving symptoms. The investigators hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Arterial Disease||Drug: Ramipril||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease|
- Time to onset of claudication
- Total exercise time during a standard treadmill test
- Walking ability measured using the standard Walking Impairment Questionnaire
- Leg Blood Flow using Duplex Ultrasound
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168467
|Melbourne, Victoria, Australia, 3004|
|Principal Investigator:||Bronwyn A Kingwell, PhD||Baker Heart Research Institute|